STALEY CAPITAL ADVISERS’s Anixa Biosciences ANIX Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio ANIX Stock Details ANIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$28K	Hold	10,000	–	–	﹤0.01%	192
2026 Q1	$25.8K	Hold	10,000	–	–	﹤0.01%	183
2025 Q4	$31.2K	Hold	10,000	–	–	﹤0.01%	191
2025 Q3	$33K	Hold	10,000	–	–	﹤0.01%	196
2025 Q2	$33K	Hold	10,000	–	–	﹤0.01%	191
2025 Q1	$28.6K	Hold	10,000	–	–	﹤0.01%	188
2024 Q4	$23.2K	Hold	10,000	–	–	﹤0.01%	178
2024 Q3	$31.5K	Hold	10,000	–	–	﹤0.01%	183
2024 Q2	$22.1K	Hold	10,000	–	–	﹤0.01%	181
2024 Q1	$31.2K	Buy	+10,000	New	+$39.9K	﹤0.01%	183

Other funds holding ANIX

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

LNWTC

Laird Norton Wetherby Trust Company Seattle, Washington $5.21B AUM 31.48% 1-Year Est. Return

DADC

D.A. Davidson & Co Great Falls, Montana $18.1B AUM 24.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

STALEY CAPITAL ADVISERS's ANIX Position: Q2 2026 in Review

STALEY CAPITAL ADVISERS held its Anixa Biosciences (ANIX) position steady in Q2 2026 at 10,000 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #192.

STALEY CAPITAL ADVISERS first reported a position in ANIX in Q1 2024 and has held it in 10 quarters since. The position peaked at $33K in Q3 2025. 63 funds tracked by Wall St. Rank hold ANIX as of Q2 2026.

STALEY CAPITAL ADVISERS held 10,000 shares of Anixa Biosciences worth $28K as of Q2 2026.
STALEY CAPITAL ADVISERS left its Anixa Biosciences share count unchanged in Q2 2026.
Anixa Biosciences made up ﹤0.01% of STALEY CAPITAL ADVISERS's portfolio in Q2 2026, its #192 holding.
STALEY CAPITAL ADVISERS first reported a position in Anixa Biosciences in Q1 2024 and has held it in 10 quarters since.
STALEY CAPITAL ADVISERS's Anixa Biosciences position peaked at $33K in Q3 2025.
63 funds tracked by Wall St. Rank held Anixa Biosciences as of Q2 2026.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q2 2026, filed 11 Aug 2026.